Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson & Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing commitment t...
Source: Johnson and Johnson - January 29, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
lopinavir and ritonavir (Kaletra)
Title: lopinavir and ritonavir (Kaletra)Category: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 11/22/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 22, 2019 Category: Drugs & Pharmacology Source Type: news
Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)
Title: Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 9/4/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 4, 2019 Category: Nutrition Source Type: news
ritonavir (Norvir)
Title: ritonavir (Norvir)Category: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 8/16/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 16, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Technivie (ombitasvir, paritaprevir and ritonavir)
Title: Technivie (ombitasvir, paritaprevir and ritonavir)Category: MedicationsCreated: 10/24/2018 12:00:00 AMLast Editorial Review: 10/24/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 24, 2018 Category: Drugs & Pharmacology Source Type: news
Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD OBV/PTV/r +/- DSV in HCV GT4-infected Patients With Severe CKD
This study investigated the real-world efficacy of ombitasvir/paritaprevir/ritonavir +/- DSV regimen in HCV genotypes 4 and 1 patients with advanced chronic kidney disease.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Effect of 3D Regimen on HRQoL for Patients With Hepatitis C Effect of 3D Regimen on HRQoL for Patients With Hepatitis C
This study investigated the impact of a RBV-free ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) regimen on health-related quality of life for HCV patients, both during and after treatment.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Protease Inhibitors May Worsen Outcomes for HIV & #43; Heart Failure
WEDNESDAY, Aug. 1, 2018 -- Ritonavir-boosted protease inhibitor (PI) therapy is associated with worse outcomes, including death, in patients with HIV and heart failure, according to a study published in the July 31 issue of the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2018 Category: Pharmaceuticals Source Type: news
Protease inhibitors may increase risk of death in people with HIV and heart failure
Ritonavir-boosted protease inhibitors associated with doubled risk of hospital readmission and cardiovascular death Related items fromOnMedica Stroke rate higher in HIV patients £30 million to tackle antimicrobial resistance Single-dose malaria drug eliminates parasite from liver Ibuprofen not a safe alternative to antibiotics for uncomplicated UTIs Too few women take part in many CVD clinical trials (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 24, 2018 Category: UK Health Source Type: news
Increased Risk of Cardiovascular Disease With Darunavir Increased Risk of Cardiovascular Disease With Darunavir
Cumulative use of ritonavir-boosted darunavir, a contemporary protease inhibitor used to treat HIV, is associated with an increasing risk of cardiovascular disease, according to results from the D:A:D study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 22, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Ombitasvir; Paritaprevir; Ritonavir (Technivie) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news
Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir (Viekira XR) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news
HIV Drug Appears Safe During Pregnancy
The study found no difference in the risk for premature birth, low birth weight or other serious complications among those who didn't receive TDF and those who got TDF along with emtricitabine and lopinavir/ritonavir. (Source: WebMD Health)
Source: WebMD Health - April 25, 2018 Category: Consumer Health News Source Type: news
